MedTrace Logo

Comparison of Platelet-Rich Plasma Dressing and Normal Saline Dressing for Wound Healing in Patients With Chronic Diabetic Wounds

NCT06867328 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2025-05-31

No results posted yet for this study

Summary

Chronic diabetic wounds are a major health concern, often taking a long time to heal and increasing the risk of complications like infections and amputations. This study aims to compare the effectiveness of Platelet-Rich Plasma (PRP) Dressing versus Normal Saline Dressing in the treatment of chronic diabetic wounds. PRP is a treatment derived from the patient's own blood that contains growth factors, which may accelerate wound healing.

Participants with chronic diabetic wounds will be randomly assigned to receive either PRP dressing or normal saline dressing. The study will measure the rate of wound healing and the time taken to achieve complete healing in both groups. It is hypothesized that PRP dressing will lead to faster and more effective wound healing compared to normal saline dressing.

Findings from this research could help improve wound care strategies for diabetic patients and provide evidence for a more effective treatment approach in clinical practice.

Conditions

  • Diabetic Wounds
  • Diabetic Ulcers

Interventions

PROCEDURE

Platelet-Rich Plasma (PRP) Dressing

* PRP will be prepared by centrifugation of 20 mL venous blood with an anticoagulant. * The extracted PRP will be applied twice weekly to the wound. * A sterile gauze will be placed over the wound after PRP application. * Treatment will continue for up to 6 weeks or until wound healing is achieved.

PROCEDURE

Normal Saline Dressing

Wound will be cleansed with normal saline and covered with sterile gauze. * Dressing changes will be done twice weekly following wound debridement. * Treatment will continue for up to 6 weeks or until wound healing is achieved.

Sponsors & Collaborators

  • Gulab Devi Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-10
Primary Completion
2025-05-10
Completion
2025-05-10

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06867328 on ClinicalTrials.gov